Bull&Bear | Lumen Technologies Surges 93% Amid $5 Billion AI-Driven Deal; Jumia Technologies Plummets 54% on Q2 Revenue Decline

On the Bullish Stocks:

Lumen Technologies (LUMN) rose by 93.05%. Lumen Technologies experienced significant growth, driven by a $5 billion new business deal that emerged due to increased connectivity demands attributed to advancements in artificial intelligence.

Bioventus (BVS) rose by 29.23%. Bioventus reported second-quarter earnings per share (EPS) of $0.19, surpassing Wall Street's estimate of $0.07, which drove its stock price up.

Clear Secure (YOU) rose by 24.19%, continuing a two-day rally for a total gain of 25.22% during this period. Clear Secure witnessed growth fueled by its NextGen ID integration and technological advancements.

Vimeo (VMEO) rose by 23.38%. Vimeo's stock surged after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance.

ReGen Corporation (RGC) rose by 23.26%. ReGen Corporation announced a breakthrough in clinical trials with their latest innovative drug aimed at treating neurodegenerative diseases. The preliminary trial results showed that the drug met both efficacy and safety standards, sparking widespread market attention and positive reaction. The company's management emphasized that this milestone not only brings new hope to patients but also lays a solid foundation for the company's future development. Analysts predict this breakthrough will significantly enhance ReGen Corporation's market competitiveness and profitability.

On the Bearish Stocks:

Jumia Technologies (JMIA) fell by 53.82%, continuing a seven-day losing streak for a total loss of 62.67% over the past week. The sharp decline in Jumia Technologies' stock price followed a drop in Q2 revenue.

TrueBlue (TBI) fell by 24.37%, continuing a five-day losing streak for a total loss of 33.17% over the past five days. The decline in TrueBlue's stock came after the company released weaker-than-expected Q2 financial results.

Chegg (CHGG) fell by 22.18%, continuing a four-day losing streak for a total loss of 33.14% over the past four days. Chegg's stock dropped following its Q2 financial report release, which included a Q3 revenue forecast below expectations. Additionally, a major investment firm maintained an under-market forecast rating and lowered the target price from $6 to $2.

Seres Therapeutics (MCRB) fell by 21.09%. Seres Therapeutics, Inc.'s business performance continues to lag behind its industry sector, resulting in a drop in its stock price.

AdaptHealth (AHCO) fell by 21.06%, continuing a five-day losing streak for a total loss of 24.10% over the past five days. AdaptHealth's stock declined following the release of its Q2 financial report.